`
`Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution May 16, 2011
`
`News
`Select
`
`Mylan Launches First Generic Version of
`Xibrom® Ophthalmic Solution
`
`
`PR Newswire
`PITTSBURGH
`
`Mylan Launches First Generic Version of Xibrom® Ophthalmic Solution
`PR Newswire
`
`PITTSBURGH, May 16, 2011
`
`PITTSBURGH, May 16, 2011 /PRNewswire/ Mylan Inc. (Nasdaq: MYL) today announced that its
`subsidiary Mylan Pharmaceuticals Inc. has launched Bromfenac Ophthalmic Solution, 0.09% (Twice
`Daily Administration), based on a development and supply agreement with Coastal Pharmaceuticals.
`This product is the first generic version of ISTA's Xibrom® Ophthalmic Solution, 0.09% (Twice Daily
`Administration), a treatment for postoperative inflammation in patients who have undergone cataract
`extraction.
`
`Bromfenac Ophthalmic Solution had U.S. sales of approximately $116 million for the 12 months ending
`March 31, 2011, according to IMS Health.
`
`Currently, Mylan has 169 ANDAs pending FDA approval representing $100.7 billion in annual sales,
`according to IMS Health. Fortyfive of these pending ANDAs are potential firsttofile opportunities,
`representing $25.8 billion in annual brand sales, for the 12 months ending Dec. 31, 2010, according to
`IMS Health.
`
`Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and
`provides products to customers in more than 150 countries and territories. The company maintains one
`of the industry's broadest and highest quality product portfolios supported by a robust product pipeline;
`operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty
`business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan,
`please visit www.mylan.com. For more information about generic drugs, please visit
`www.ChoosingGenerics.com.
`
`SOURCE Mylan Inc.
`
`http://newsroom.mylan.com/pressreleases?item=122986
`
`1/1